MA26550A1 - HETEROMATIC COMPOUNDS AND THEIR USES IN MEDICINE - Google Patents

HETEROMATIC COMPOUNDS AND THEIR USES IN MEDICINE

Info

Publication number
MA26550A1
MA26550A1 MA25280A MA25280A MA26550A1 MA 26550 A1 MA26550 A1 MA 26550A1 MA 25280 A MA25280 A MA 25280A MA 25280 A MA25280 A MA 25280A MA 26550 A1 MA26550 A1 MA 26550A1
Authority
MA
Morocco
Prior art keywords
heteromatic
medicine
compounds
heteromatic compounds
Prior art date
Application number
MA25280A
Other languages
French (fr)
Inventor
Mui Cheung
Kimberly Caroline Glennon
Karen Elisabeth Lackey
Michael Robert Peel
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26550A1 publication Critical patent/MA26550A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
MA25280A 1997-10-10 1998-10-06 HETEROMATIC COMPOUNDS AND THEIR USES IN MEDICINE MA26550A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721437.3A GB9721437D0 (en) 1997-10-10 1997-10-10 Heteroaromatic compounds and their use in medicine

Publications (1)

Publication Number Publication Date
MA26550A1 true MA26550A1 (en) 2004-12-20

Family

ID=10820303

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25280A MA26550A1 (en) 1997-10-10 1998-10-06 HETEROMATIC COMPOUNDS AND THEIR USES IN MEDICINE

Country Status (7)

Country Link
AR (1) AR017311A1 (en)
AU (1) AU1151099A (en)
GB (1) GB9721437D0 (en)
MA (1) MA26550A1 (en)
PE (1) PE120199A1 (en)
WO (1) WO1999021859A1 (en)
ZA (1) ZA989249B (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69838172T2 (en) 1997-08-22 2008-04-10 Astrazeneca Ab OXINDOLYLCHINAZOLE DERIVATIVES AS ANGIOGENESEHEMMER
HU230000B1 (en) 1999-02-10 2015-04-28 Astrazeneca Ab Intermediates for the preparation of angiogenesis inhibitory quinazoline derivatives
US20030143676A1 (en) * 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
US7083791B2 (en) 1999-03-25 2006-08-01 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
EP1088821A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
SE9904177D0 (en) * 1999-11-18 1999-11-18 Astra Ab Novel compounds
EP1244672B1 (en) * 1999-12-21 2005-07-20 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
US6323029B1 (en) 2000-01-19 2001-11-27 Isis Pharmaceuticals, Inc. Antisense modulation of glycogen synthase kinase 3 beta expression
US6316259B1 (en) 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
WO2001056557A2 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
FR2804959B1 (en) * 2000-02-15 2006-04-28 Centre Nat Rech Scient USE OF PAULLON DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS
US6465507B2 (en) 2000-02-28 2002-10-15 Sugen, Inc. 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
AU2001276521B2 (en) 2000-08-09 2006-05-25 Astrazeneca Ab Cinnoline compounds
CA2415469A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
JP2004518662A (en) * 2000-12-19 2004-06-24 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Pyrazolo [3,4-C] pyridines as GSK-3 inhibitors
US6706724B2 (en) 2000-12-21 2004-03-16 Nitromed, Inc. Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
SE0101230L (en) * 2001-04-06 2002-10-07 Innoventus Project Ab New use of a tyrosine kinase inhibitor
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
US7390808B2 (en) * 2001-04-30 2008-06-24 Vertex Pharmaceuticals Incorporated Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes
EP1401415B1 (en) 2001-06-29 2006-06-21 AB Science Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
ATE343415T1 (en) 2001-06-29 2006-11-15 Ab Science THE USE OF C-KIT INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
EP1434991B1 (en) 2001-06-29 2007-10-17 AB Science New potent, selective and non toxic c-kit inhibitors
WO2003002106A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitions for treating allergic diseases
EP1430053B1 (en) * 2001-09-27 2006-10-25 SmithKline Beecham Corporation AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN
AU2003202094B2 (en) 2002-02-01 2009-10-08 Astrazeneca Ab Quinazoline compounds
WO2003082868A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
AU2003214414B2 (en) 2002-03-28 2008-10-09 Eisai R & D Management Co., Ltd. Azaindoles as inhibitors of c-Jun N-terminal kinases
CA2484797A1 (en) * 2002-05-06 2003-11-13 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
WO2004078756A2 (en) 2003-03-06 2004-09-16 Eisai Co., Ltd. Jnk inhibitors
WO2004101565A2 (en) 2003-05-16 2004-11-25 Eisai Co., Ltd. Jnk inhibitors
AR045037A1 (en) 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0402137D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP2332940B1 (en) * 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
CN1953974A (en) * 2004-05-14 2007-04-25 辉瑞产品有限公司 Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005113561A1 (en) * 2004-05-20 2005-12-01 Sugen, Inc. Cyclicsulfonate pyrrole indolinones as kinase inhibitors
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
JP2009503001A (en) * 2005-08-01 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー Heterocyclic benzylamino derivatives, their production and use as pharmaceuticals
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (en) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Regulation of neurogenesis by PDE inhibition
ES2380236T3 (en) 2005-10-28 2012-05-09 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CN102532134A (en) 2006-01-17 2012-07-04 沃泰克斯药物股份有限公司 Azaindoles useful as inhibitors of janus kinases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2013207B1 (en) 2006-04-26 2012-04-25 Cancer Research Technology Limited Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8247421B2 (en) 2006-12-21 2012-08-21 Vertex Pharmaceuticals Incorporated 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
KR101665143B1 (en) 2007-12-19 2016-10-11 캔써 리서치 테크놀로지 리미티드 Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TWI574963B (en) 2009-06-17 2017-03-21 維泰克斯製藥公司 Inhibitors of influenza viruses replication
CN102906090B (en) 2010-02-01 2015-06-24 癌症研究技术有限公司 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
US8846909B2 (en) 2010-05-24 2014-09-30 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
RU2013132681A (en) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед INFLUENZA VIRUS REPLICATION INHIBITORS
CN102115469A (en) * 2011-03-21 2011-07-06 浙江大学 Preparation method for indoline-2-one derivative and application of same
US8669363B2 (en) 2011-03-24 2014-03-11 Southern Methodist University Quinoxaline compounds and derivatives
US9493452B2 (en) * 2011-03-24 2016-11-15 Southern Methodist University Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
CA2839937C (en) 2011-07-05 2020-11-03 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
ES2748873T3 (en) 2012-01-26 2020-03-18 Angion Biomedica Corp Antifibrotic compounds and uses thereof
WO2013142831A1 (en) 2012-03-23 2013-09-26 Southern Methodist University Methods of making and using thioxothiazolidine and rhodanine derivatives as hiv-1 and jsp-1 inhibitors
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
ES2741444T3 (en) 2013-11-13 2020-02-11 Vertex Pharma Inhibitors of influenza virus replication
SI3421468T1 (en) 2013-11-13 2021-03-31 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN104447733B (en) * 2015-01-05 2016-08-17 中国药科大学 1-benzyl-2-pyrrolinone-4-amides compound and preparation method and application
CN104876928B (en) * 2015-05-07 2016-09-14 浙江司太立制药股份有限公司 7-azaindole quinoline-2-ketone compounds and preparation method thereof
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
MA42422A (en) 2015-05-13 2018-05-23 Vertex Pharma INHIBITORS OF INFLUENZA VIRUS REPLICATION
NZ742228A (en) * 2015-11-12 2019-09-27 Lg Chemical Ltd Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
SG11201810704WA (en) 2016-05-31 2018-12-28 Taiho Pharmaceutical Co Ltd Sulfonamide compound or salt thereof
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
CN106432228A (en) * 2016-09-06 2017-02-22 浙江司太立制药股份有限公司 4-oximido-1-piperidyl fragment containing 7-azaindolin-2-one compound and preparation method therefor
CN106397436A (en) * 2016-09-06 2017-02-15 浙江司太立制药股份有限公司 5-bromo-7-azaindoline-2-one compounds and preparation method thereof
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation

Also Published As

Publication number Publication date
PE120199A1 (en) 1999-12-15
WO1999021859A1 (en) 1999-05-06
AU1151099A (en) 1999-05-17
GB9721437D0 (en) 1997-12-10
AR017311A1 (en) 2001-09-05
ZA989249B (en) 2000-04-10

Similar Documents

Publication Publication Date Title
MA26550A1 (en) HETEROMATIC COMPOUNDS AND THEIR USES IN MEDICINE
DE69618587D1 (en) CHINAZOLINE AND PHARMACEUTICAL COMPOSITIONS
NO20002359L (en) Adenosine derivatives and pharmaceutical composition containing the derivatives
NO944046D0 (en) Increase in drug response
HUP0101137A3 (en) Anticoagulant amidines and their pharmaceutical use
PT908456E (en) PIRAZOLE DERIVATIVES AND THEIR PRODUCTION AND THEIR USE IN MEDICINES
EE04566B1 (en) Epothilone derivatives and their use in medicine
PT1270565E (en) 4-SUBSTITUTED FURANO-2-SULFONAMIDE AND ITS USE IN THE PREPARATION OF SULFONYLURY DERIVATIVES
IL131319A0 (en) 3-Piperidyl-4- oxoquinazoline derivatives and medicinal compositions containing the same
BR9607851B1 (en) combination and pharmaceutical formulation.
MA26553A1 (en) ALPHA-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
LV12624A (en) Thienylazolylalcoxyethanamines their preparation and their application as medicaments
DE69300913D1 (en) Polymorph terazosin and pharmaceutical composition.
IL133097A0 (en) Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof
NO20021001D0 (en) Radiopharmaceutical products and their manufacture
BR9509688A (en) Pharmaceutical composition and composition
ITMI942663A0 (en) PROTEINS RICH IN HYDROXYPROLINE AND THE PHARMACEUTICAL AND COSMETIC FORMULATIONS THAT COMPOSE THEM
FR2766737B1 (en) MULTIPLE EMULSIONS AND THEIR APPLICATIONS
DE69809928D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING TIZOXANIDE AND NITAZOXANIDE
NO942228D0 (en) Ipsapirone drug preparation
DE69900336T2 (en) PENTOXIFYLLIN AND ANTIZYTOKIN PHARMACEUTICAL COMPOSITIONS
BR9505130A (en) Pharmaceutical composition and composition
ES1027140Y (en) MEDICINAL AND SIMILAR PILLS CRUSHER.
SE9703737D0 (en) Pharmaceutical composition and use
BR1100391A (en) Pharmaceutical composition and composition